Abbott closes $310M stent deal; GeneNews slashing 60% of workforce;

@FierceMedDev: Popular this week: Inventor launches crowdfunding hub for medical devices. Article | Follow @FierceMedDev

@DamianFierce: Finally, some good news for Navidea: Medicare expansion and a Siemens partnership. Report | Follow @DamianFierce

@MarkHFierce: In 2012, medical device employment at the top companies mostly grew, due to M&A and organic growth. ICYM the feature | Follow @MarkHFierce

> Abbott Laboratories ($ABT) has wrapped up its $310 million deal for IDEV Technologies. Release

> Canadian diagnostics outfit GeneNews ($GEN) plans to cut 60% of its staff by Nov. 30. Item

> San Diego's Tensys Medical won Chinese approval for its TL-300 patient monitoring system, and it plans to launch the device immediately through a local partner. News

> Reverse Medical snagged FDA clearance for its MVP vascular plug designed for peripheral artery embolization. More

> Exosome Diagnostics has teamed up with the Icahn School of Medicine at Mount Sinai to develop in vitro tests for cancer, inflammatory diseases and other ailments. More

> Arizona startup HealthTell raised $4 million to develop diagnostic tests for lung, breast, prostate and colorectal cancers. Report

> Taiwan's Apex Medical is fighting back against ResMed's patent challenge over sleep apnea devices. Story

Biotech News

@FierceBiotech: Popular yesterday: Novartis wins a record breakthrough therapy designation for orphan drug. Article | Follow @FierceBiotech

@JohnCFierce: Just came across my story on first IPO of '13 - $STML, priced at $10, now $34.55. Hopeful signs, indeed. Article | Follow @JohnCFierce

@EmilyMFierce: This week's issue of FierceBiotechResearchReport | Follow @EmilyMFierce

> Basilea shares dented after FDA digs in on antibiotic PhIII rule. Story

> Trial co-op persuades pharmas to stop sabotaging head-to-head drug studies. More

> Incyte shares surge on positive pancreatic cancer trial data for Jakafi. News

Pharma News

@FiercePharma: Novartis picks Dublin site for new regional business center, on track for 100 new jobs there. More | Follow @FiercePharma

@EricPFierce: Alexion recalls some Soliris in EC "due to the presence of visible particles in a limited number of vials." More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Shire enlists help fighting unwanted takeover. Another co. seeking access to Ireland's tax regime? Popular yesterday from FiercePharma | Follow @CarlyHFierce

> China's pharma probe intensifies with British consultant's arrest. More

> India's Biocon promises Herceptin biosim launch by fiscal year-end. Article

> Allergan pushes FDA to defend Restasis from early generics. Report

Biomarkers News

> Blood samples may aid suicide risk prediction. Story

> Possible psychosis biomarker found in brain "folding." Story

> Potential Alzheimer's biomarker targeted in brain fluid. More

> Lung cancer gene variants could help boost survival odds. Article

> Biomarker gauges graft-versus-host disease risk for stem cell transplant patients. Item

Drug Delivery News

@MichaelGFierce: Time-release delivery of vision-loss drug demands fewer injections. More | Follow @MichaelGFierce

> Study: Insulin pumps improve glycemic control in children with diabetes. Story

> Bind launches second PhII trial for prostate cancer nanomed. More

> Alnylam wins two orphan designations for hemophilia RNAi drug. Report

> Platinum-based radiotherapy method zaps cancer with nanomeds. Article

Suggested Articles

In an SEC filing, Baxter International disclosed that it may have overstated its income over multiple years, inflating it by about $276 million.

The FDA has given Grail a green light to conduct the interventional study, and it has begun enrolling participants through the company’s R&D partners.

Coronavirus may not require a front-line battle yet in certain places, but it’s still taxing public health officials preparing for a potential crisis.